NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









EpilepsyGTx

EpilepsyGTx

Private
CanterburyHealthcare & Life Scienceshttps://www.epilepsygtx.com/

Last Round

Series A

Dec 10, 2025

Total Funding Raised

$43M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

EpilepsyGTx is a biotechnology company developing cutting-edge gene therapies to treat focal refractory epilepsy.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyadeno-associated viralAAVfocal refractory epilepsyepilepsy treatmentbiotechprecision medicineneurologydrug discoveryclinical trialsgenetic medicineneurological disordersbiotech startupgenomics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EpilepsyGTx Comparables

Compare EpilepsyGTx with similar companies based on industry and business-model similarity.

EpilepsyGTx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Latus Bio
84%
Capsida Biotherapeutics
81%
Kriya Therapeutics
80%

EpilepsyGTx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 10, 2025
SeedJun 24, 2024

Key People

Founding team and executive leadership

Jan Thirkettle

Chief Executive Officer

Executive Team

Nicolas Koebel

Chief Executive Officer

Executive Team

EpilepsyGTx Investors

Notable investors and investment history

EpilepsyGTx investors
InvestorRounds
XGEN VentureSeries A
British Business BankSeries A
UCL BusinessSeed
Albion CapitalSeed
ZcubeSeed
Health Technology HoldingSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 29, 2026

    Professor Dimitri Kullmann appointed as the new CSO.

EpilepsyGTx Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

EpilepsyGTx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EpilepsyGTx's valuation, stock price, and market status.

Firmographic Details

HeadquartersCanterbury
Employee Range8
Year Founded2021
Last FundingDec 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.